NY-CPV
2.4.2024 15:01:33 CEST | Business Wire | Press release
Cohen Private Ventures (CPV), the family office of Steven A. Cohen, is proud to officially unveil New York Golf Club (NYGC) and its four-player roster of PGA TOUR stars featuring Rickie Fowler, Xander Schauffele, Matt Fitzpatrick and New York-native Cameron Young ahead of the inaugural 2025 TGL presented by SoFi season.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240402326760/en/
New York Golf Club team roster: Cameron Young, Matt Fitzpatrick, Xander Schauffele, Rickie Fowler (Photo: Business Wire)
New York is synonymous with world class, and its golf scene is no exception. Steeped in the history of the sport, with some of the greatest and most iconic courses in the world, NYGC is ready to build upon its rich legacy of golf and redefine what it means to be a golf club representing a city known for its constant reinvention. NYGC is excited to represent the tri-state area in this innovative and accessible version of the sport.
“New Yorkers expect and deserve the best, and we couldn’t be more excited to have four of the best players in the world serve as an extension of the thriving golf and sporting culture of our city and region,” said Steve Cohen, owner of the NYGC and the New York Mets. “Rickie, Xander, Matt, and Cameron’s unwavering dedication to the sport, successful track records, and passion for winning is undisputable, and we look forward to watching them compete on golf’s newest stage.”
TEAM NAME & LOGO
New York City is the greatest city in the world, and NYGC embraces the privilege and responsibility that comes with representing the five boroughs and surrounding communities. NYGC will build upon our world-class golfing and sports heritage to deliver a team New York fans can be proud of.
NYGC’s logo is inspired by New York’s state bird, the Eastern Bluebird. These birds are commonly found where forests meet fields, and particularly on golf courses. Our design features a dynamic swinging club crafted into the form of a wing with four grooves, one for each of our players. The circle pays homage to the circles on our scorecards and the iconic NYC Subway circle.
MEET THE PLAYERS
Fowler is one of the most popular players on the PGA TOUR. Since turning professional in 2009, he has recorded 10 professional wins, including the 2015 PLAYERS Championship. His most recent title came at the 2023 Rocket Mortgage Classic in July. Fowler brings a wealth of team golf experience as a veteran of five U.S. Ryder Cup teams, three U.S. Presidents Cup teams, one World Cup, Walker Cup and Palmer Cup teams from his time as an amateur player. He also represented the U.S. in the 2016 Olympic Games.
“I am thrilled to be joining New York Golf Club for the inaugural TGL season,” said Fowler. “It is an incredible opportunity to represent one of the greatest cities in the world, and I look forward to competing in 2025.”
Schauffele, currently No. 5 in the Official World Golf Ranking, has been a top-10 player in the world for the better part of the last five years and regularly placing in the Top 10 of major championships. Since turning professional in 2015, he has recorded seven PGA TOUR titles, two DP World Tour wins and an Olympic Gold Medal in Tokyo. He was named the PGA TOUR Rookie of the Year in 2016-2017 and represented the U.S. in two Presidents Cup teams and two Ryder Cup teams.
“I’ve built my career on a foundation of hard work, grit, and determination, which couldn’t better reflect the people of New York City,” said Schauffele. “It’s a true honor to both grow the game and represent this incredible city.”
Fitzpatrick became England’s first major champion since 2016 when he won the 2022 U.S. Open at The Country Club in Brookline, Massachusetts, joining Jack Nicklaus as the only players to have won a U.S. Open and U.S. Amateur at the same venue. Since turning professional in 2014, Fitzpatrick has recorded two PGA TOUR titles and eight international victories, and represented England on three European Ryder Cup teams. His most recent PGA TOUR victory came at the RBC Heritage in April 2023.
“Working with the team at Cohen Private Ventures on the launch of New York Golf Club has been an incredible experience,” said Fitzpatrick. “New York is one of the greatest cities in the world, and I could not be more excited to continue to deepen my connections there.”
The New York-native Young is quickly becoming a fan favorite on the PGA TOUR. In 2022, Young earned Rookie of the Year honors when he became the seventh player since 1980 to collect five runner-up finishes in a season, including a second-place finish at The Open Championship and tying for third at the PGA Championship. He made his debut on the Presidents Cup team in 2022. Cameron’s father David Young, recently retired after over 20 years as Sleepy Hollow Country Club’s Head Golf Professional.
“Having grown up a New Yorker, first learning to play at Sleepy Hollow, the opportunity to represent New York Golf Club feels surreal,” said Young. “Alongside Rickie, Xander, and Matt, I am confident we are going to be a highly competitive team in the upcoming TGL season.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402326760/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
